Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
18F-FB-RMSH-1 is a radiofluorinated metallopeptide developed as a molecular probe for positron emission tomography (PET) imaging of tumors expressing the melanocortin 1 receptor (MC1R), particularly malignant melanoma. It is a specific isomer of the rhenium-cyclized alpha-melanocyte-stimulating hormone (alpha-MSH) analog, Ac-d-Lys-ReCCMSH(Arg(11)), labeled with fluorine-18 via N-succinimidyl-4-18F-fluorobenzoate (18F-SFB). In preclinical studies, 18F-FB-RMSH-1 demonstrated high binding affinity to MC1R and superior in vivo performance compared to its isomer 18F-FB-RMSH-2, characterized by higher tumor uptake and significantly lower accumulation in the kidneys and liver. This profile makes it a promising candidate for the non-invasive detection and monitoring of MC1R-positive malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 18F-FB-RMSH-1.